

**CORRECTION**

**Open Access**

# Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

Yoon-La Choi<sup>1,2†</sup>, Ensel Oh<sup>3,4†</sup>, Sarah Park<sup>5</sup>, Yeonju Kim<sup>6</sup>, Yeon-Hee Park<sup>7</sup>, Kyug Song<sup>3</sup>, Eun Yoon Cho<sup>2</sup>, Yun-Chul Hong<sup>8</sup>, Jong Sun Choi<sup>9</sup>, Jeong Eon Lee<sup>10</sup>, Jung Han Kim<sup>10</sup>, Seok Jin Nam<sup>10</sup>, Young-Hyuck Lim<sup>7</sup>, Jung-Hyun Yang<sup>10</sup>, Young Kee Shin<sup>3,4\*</sup>

**Correction**

After the publication of this work [1], we found that there were some mistakes in calculating the percentage of composition in Table 1 (1). Clinicopathologic characteristics of

breast cancer subtypes. We are therefore providing the revised Table 1, with the updated data for rows 'Mucinous carcinoma', 'Metaplastic carcinoma' and 'Others'. In the sub-content of Table 1, 'Histological type', the total

**Table 1. Clinicopathologic characteristics of breast cancer subtypes**

Variables	All N=951		Molecular Subtyping										P value between five subtypes *,†	P value between four subtypes **,†		
			IHC-Luminal A		IHC-Luminal B		IHC-HER2		Five subtypes						Four subtypes	
			N=486 51.1%		N=123 12.9%		N=113 11.9%		IHC-BLBC N=139 14.6%		IHC-QNBC/SNP N=90 9.5%				IHC-TNBC N=229 24.1%	
			No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)			No.	(%)
Age Group (years)																
<50	590	62.0	297	61.1	87	70.7	51	45.1	97	69.8	58	64.4	155	67.7	<0.001	<0.001
≥50	361	38.0	189	38.9	36	29.3	62	54.9	42	30.2	32	35.6	74	32.3		
Family history of breast cancer																
No	916	96.3	470	96.7	121	98.4	111	98.2	126	90.6	88	97.8	214	93.4	0.006	0.086
Yes	35	3.7	16	3.3	2	1.6	2	1.8	13	9.4	2	2.2	15	6.6		
Tumor Size																
≤ 2 cm	392	41.2	228	46.9	39	31.7	35	31.0	52	37.4	38	42.2	90	39.3	0.014	0.006
2-5 cm	493	51.8	231	47.5	75	61.0	64	56.6	76	54.7	47	52.2	123	53.7		
> 5cm	66	6.9	27	5.6	9	7.3	14	12.4	11	7.9	5	5.6	16	7.0		
N Staging																
N0	498	52.4	246	50.6	52	42.3	63	55.8	89	64.0	48	53.3	137	59.8	0.178	0.014
N1	247	25.9	131	27.0	40	32.5	22	19.5	31	22.3	23	25.6	54	23.6		
N2	118	12.4	64	13.2	19	15.4	13	11.5	12	8.6	10	11.1	22	9.6		
N3	88	9.2	45	9.3	12	9.8	15	13.3	7	5.0	9	10.0	16	7.0		
AJCC stage																
I	254	26.7	148	30.5	19	15.4	22	19.5	38	27.3	27	30.0	65	28.4	0.014	0.008
II	467	49.1	221	45.5	69	56.1	57	50.4	78	56.1	42	46.7	120	52.4		
III	230	24.2	117	24.1	35	28.5	34	30.1	23	16.5	21	23.3	44	19.2		
LN involvement																
Negative	498	52.4	246	50.6	52	42.3	63	55.8	89	64.0	48	53.3	137	59.8	0.016	0.020
Positive	453	47.6	240	49.4	71	57.7	50	44.2	50	36.0	42	46.7	92	40.2		
Nuclear Grade																
Low	92	9.7	67	13.8	5	4.1	3	2.7	9	6.5	8	8.8	17	7.4	<0.001	<0.001
Intermediate	486	51.1	308	63.4	65	52.8	40	35.4	26	18.7	47	52.2	73	31.9		
High	373	39.2	111	22.8	53	43.1	70	61.9	104	74.8	35	38.9	139	60.7		
Histological Grade																
Well	100	10.5	63	13.0	10	8.1	11	9.7	8	5.8	8	8.9	16	7.0	<0.001	<0.001
Moderate	597	62.8	334	68.7	76	61.8	65	57.5	71	51.1	51	56.7	122	53.3		
Poor	254	26.7	89	18.3	37	30.1	37	32.7	60	43.2	31	34.4	91	39.7		
Estrogen Receptor (ER)																
Negative	364	38.3	11	2.3	11	8.9	113	100.0	139	100.0	90	100.0	229	100.0	<0.001	<0.001
Positive	587	61.7	475	97.7	112	91.1	0	0.0	0	0.0	0	0.0	0	0.0		

**Figure 1**

\* Correspondence: ykeeshin@snu.ac.kr

† Contributed equally

<sup>3</sup>Research Institute of Pharmaceutical Science

Full list of author information is available at the end of the article

number of 'Others' was corrected from 18 to 16, and the composition of 'Others' type was slightly changed according to breast cancer subtypes. For IHC-Her2 subtype, the number of 'Others' was changed from 4 to 3, and 6 cases which were previously unidentified were assigned to corresponding subtypes. One case to IHC-BLBC, 2 cases to IHC-QNBC/5NP and 3 cases to IHC-TNCB. There was no effect on statistical analysis with the correction.

#### Author details

<sup>1</sup>Laboratory of Cancer Genomics and Molecular Pathology. <sup>2</sup>Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. <sup>3</sup>Research Institute of Pharmaceutical Science. <sup>4</sup>Interdisciplinary Program of Bioinformatics, Department of Pharmacy, Seoul National University College of Pharmacy, Seoul, Korea. <sup>5</sup>Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's hospital, Catholic University, Seoul, Korea. <sup>6</sup>Cancer Early Detection Branch, National Cancer Control Research Institute, National Cancer Center, Goyang, Korea. <sup>7</sup>Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. <sup>8</sup>Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. <sup>9</sup>Department of Pathology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea. <sup>10</sup>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Received: 11 January 2011 Accepted: 12 January 2011  
Published: 12 January 2011

#### Reference

1. Choi YL, Oh E, Park S, *et al*: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. *BMC Cancer* 10:507.

#### Pre-publication history

The pre-publication history for this paper can be accessed here:  
<http://www.biomedcentral.com/1471-2407/11/13/prepub>

doi:10.1186/1471-2407-11-13

**Cite this article as:** Choi *et al*: Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. *BMC Cancer* 2011 11:13.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

